@article{
 title = {Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95},
 type = {article},
 year = {2008},
 identifiers = {[object Object]},
 keywords = {brain-tumors,childrens-cancer-group,clinical-significance,cranial irradiation,dana-farber,medical-research-council,multicenter randomized-trial,oncology-group,phase-iii,term follow-up},
 pages = {4477-4489},
 volume = {111},
 websites = {<Go to ISI>://000255387400015},
 id = {aa2e7ce7-fc49-307a-9148-dec0f33e4ff9},
 created = {2015-02-12T14:34:57.000Z},
 file_attached = {false},
 profile_id = {81af7548-db00-3f00-bfa0-1774347c59e1},
 group_id = {63e349d6-2c70-3938-9e67-2f6483f6cbab},
 last_modified = {2015-02-12T20:24:08.000Z},
 read = {false},
 starred = {false},
 authored = {false},
 confirmed = {true},
 hidden = {false},
 source_type = {Journal Article},
 language = {English},
 notes = {<m:note>294EO<m:linebreak/>Times Cited:85<m:linebreak/>Cited References Count:74</m:note>},
 abstract = {The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed to reduce acute and long-term toxicity in selected patient groups with favorable prognosis and to improve outcome in poor-risk groups by treatment intensification. These aims were pursued through a stratification strategy using white blood cell count, age, immunophenotype, treatment response, and unfavorable genetic aberrations providing an excellent discrimination of risk groups. Estimated 6-year event-free survival (6y-pEFS) for all 2169 patients was 79.6% (+/- 0.9%). The large standard-risk (SR) group (35% of patients) achieved an excellent 6y-EFS of 89.5% (+/- 1.1%) despite significant reduction of anthracyclines. In the medium-risk (MR) group (53% of patients), 6y-pEFS was 79.7% (+/- 1.2%); no improvement was accomplished by the randomized use of additional intermediate-dose cytarabine after consolidation. Omission of preventive cranial irradiation in non-T-ALL MR patients was possible without significant reduction of EFS, although the incidence of central nervous system relapses increased. In the high-risk (HR) group (12% of patients), intensification of consolidation/reinduction treatment led to considerable improvement over the previous ALL-BFM trials yielding a 6y-pEFS of 49.2% (+/- 3.2%). Compared without previous trial ALL-BFM 90, consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients.},
 bibtype = {article},
 author = {Schrappe, M and Moricke, A and Reiter, A and Zimmermann, M and Gadner, H and Stanulla, M and Dordelmann, M and Loning, L and Beier, R and Ludwig, W D and Ratei, R and Harbott, J and Boos, J and Mann, G and Niggli, F and Feldges, A and Henze, G and Welte, K and Beck, J D and Klingebiel, T and Niemeyer, C and Zintl, F and Bode, U and Urban, C and Wehinger, H and Niethammer, D and Riehm, H and Stu, German Austrian Swill A L L B F M},
 journal = {Blood},
 number = {9}
}

{"_id":"eWdBDtp4N63pCW67k","bibbaseid":"schrappe-moricke-reiter-zimmermann-gadner-stanulla-dordelmann-loning-etal-riskadjustedtherapyofacutelymphoblasticleukemiacandecreasetreatmentburdenandimprovesurvivaltreatmentresultsof2169unselectedpediatricandadolescentpatientsenrolledinthetrialallbfm95-2008","downloads":0,"creationDate":"2017-01-12T21:32:07.736Z","title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","author_short":["Schrappe, M.","Moricke, A.","Reiter, A.","Zimmermann, M.","Gadner, H.","Stanulla, M.","Dordelmann, M.","Loning, L.","Beier, R.","Ludwig, W., D.","Ratei, R.","Harbott, J.","Boos, J.","Mann, G.","Niggli, F.","Feldges, A.","Henze, G.","Welte, K.","Beck, J., D.","Klingebiel, T.","Niemeyer, C.","Zintl, F.","Bode, U.","Urban, C.","Wehinger, H.","Niethammer, D.","Riehm, H.","Stu, G., A., S., A., L., L., B., F., M."],"year":2008,"bibtype":"article","biburl":null,"bibdata":{"title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","type":"article","year":"2008","identifiers":"[object Object]","keywords":"brain-tumors,childrens-cancer-group,clinical-significance,cranial irradiation,dana-farber,medical-research-council,multicenter randomized-trial,oncology-group,phase-iii,term follow-up","pages":"4477-4489","volume":"111","websites":"<Go to ISI>://000255387400015","id":"aa2e7ce7-fc49-307a-9148-dec0f33e4ff9","created":"2015-02-12T14:34:57.000Z","file_attached":false,"profile_id":"81af7548-db00-3f00-bfa0-1774347c59e1","group_id":"63e349d6-2c70-3938-9e67-2f6483f6cbab","last_modified":"2015-02-12T20:24:08.000Z","read":false,"starred":false,"authored":false,"confirmed":"true","hidden":false,"source_type":"Journal Article","language":"English","notes":"<m:note>294EO<m:linebreak/>Times Cited:85<m:linebreak/>Cited References Count:74</m:note>","abstract":"The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed to reduce acute and long-term toxicity in selected patient groups with favorable prognosis and to improve outcome in poor-risk groups by treatment intensification. These aims were pursued through a stratification strategy using white blood cell count, age, immunophenotype, treatment response, and unfavorable genetic aberrations providing an excellent discrimination of risk groups. Estimated 6-year event-free survival (6y-pEFS) for all 2169 patients was 79.6% (+/- 0.9%). The large standard-risk (SR) group (35% of patients) achieved an excellent 6y-EFS of 89.5% (+/- 1.1%) despite significant reduction of anthracyclines. In the medium-risk (MR) group (53% of patients), 6y-pEFS was 79.7% (+/- 1.2%); no improvement was accomplished by the randomized use of additional intermediate-dose cytarabine after consolidation. Omission of preventive cranial irradiation in non-T-ALL MR patients was possible without significant reduction of EFS, although the incidence of central nervous system relapses increased. In the high-risk (HR) group (12% of patients), intensification of consolidation/reinduction treatment led to considerable improvement over the previous ALL-BFM trials yielding a 6y-pEFS of 49.2% (+/- 3.2%). Compared without previous trial ALL-BFM 90, consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients.","bibtype":"article","author":"Schrappe, M and Moricke, A and Reiter, A and Zimmermann, M and Gadner, H and Stanulla, M and Dordelmann, M and Loning, L and Beier, R and Ludwig, W D and Ratei, R and Harbott, J and Boos, J and Mann, G and Niggli, F and Feldges, A and Henze, G and Welte, K and Beck, J D and Klingebiel, T and Niemeyer, C and Zintl, F and Bode, U and Urban, C and Wehinger, H and Niethammer, D and Riehm, H and Stu, German Austrian Swill A L L B F M","journal":"Blood","number":"9","bibtex":"@article{\n title = {Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95},\n type = {article},\n year = {2008},\n identifiers = {[object Object]},\n keywords = {brain-tumors,childrens-cancer-group,clinical-significance,cranial irradiation,dana-farber,medical-research-council,multicenter randomized-trial,oncology-group,phase-iii,term follow-up},\n pages = {4477-4489},\n volume = {111},\n websites = {<Go to ISI>://000255387400015},\n id = {aa2e7ce7-fc49-307a-9148-dec0f33e4ff9},\n created = {2015-02-12T14:34:57.000Z},\n file_attached = {false},\n profile_id = {81af7548-db00-3f00-bfa0-1774347c59e1},\n group_id = {63e349d6-2c70-3938-9e67-2f6483f6cbab},\n last_modified = {2015-02-12T20:24:08.000Z},\n read = {false},\n starred = {false},\n authored = {false},\n confirmed = {true},\n hidden = {false},\n source_type = {Journal Article},\n language = {English},\n notes = {<m:note>294EO<m:linebreak/>Times Cited:85<m:linebreak/>Cited References Count:74</m:note>},\n abstract = {The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed to reduce acute and long-term toxicity in selected patient groups with favorable prognosis and to improve outcome in poor-risk groups by treatment intensification. These aims were pursued through a stratification strategy using white blood cell count, age, immunophenotype, treatment response, and unfavorable genetic aberrations providing an excellent discrimination of risk groups. Estimated 6-year event-free survival (6y-pEFS) for all 2169 patients was 79.6% (+/- 0.9%). The large standard-risk (SR) group (35% of patients) achieved an excellent 6y-EFS of 89.5% (+/- 1.1%) despite significant reduction of anthracyclines. In the medium-risk (MR) group (53% of patients), 6y-pEFS was 79.7% (+/- 1.2%); no improvement was accomplished by the randomized use of additional intermediate-dose cytarabine after consolidation. Omission of preventive cranial irradiation in non-T-ALL MR patients was possible without significant reduction of EFS, although the incidence of central nervous system relapses increased. In the high-risk (HR) group (12% of patients), intensification of consolidation/reinduction treatment led to considerable improvement over the previous ALL-BFM trials yielding a 6y-pEFS of 49.2% (+/- 3.2%). Compared without previous trial ALL-BFM 90, consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients.},\n bibtype = {article},\n author = {Schrappe, M and Moricke, A and Reiter, A and Zimmermann, M and Gadner, H and Stanulla, M and Dordelmann, M and Loning, L and Beier, R and Ludwig, W D and Ratei, R and Harbott, J and Boos, J and Mann, G and Niggli, F and Feldges, A and Henze, G and Welte, K and Beck, J D and Klingebiel, T and Niemeyer, C and Zintl, F and Bode, U and Urban, C and Wehinger, H and Niethammer, D and Riehm, H and Stu, German Austrian Swill A L L B F M},\n journal = {Blood},\n number = {9}\n}","author_short":["Schrappe, M.","Moricke, A.","Reiter, A.","Zimmermann, M.","Gadner, H.","Stanulla, M.","Dordelmann, M.","Loning, L.","Beier, R.","Ludwig, W., D.","Ratei, R.","Harbott, J.","Boos, J.","Mann, G.","Niggli, F.","Feldges, A.","Henze, G.","Welte, K.","Beck, J., D.","Klingebiel, T.","Niemeyer, C.","Zintl, F.","Bode, U.","Urban, C.","Wehinger, H.","Niethammer, D.","Riehm, H.","Stu, G., A., S., A., L., L., B., F., M."],"urls":{"Website":"<Go to ISI>://000255387400015"},"bibbaseid":"schrappe-moricke-reiter-zimmermann-gadner-stanulla-dordelmann-loning-etal-riskadjustedtherapyofacutelymphoblasticleukemiacandecreasetreatmentburdenandimprovesurvivaltreatmentresultsof2169unselectedpediatricandadolescentpatientsenrolledinthetrialallbfm95-2008","role":"author","keyword":["brain-tumors","childrens-cancer-group","clinical-significance","cranial irradiation","dana-farber","medical-research-council","multicenter randomized-trial","oncology-group","phase-iii","term follow-up"],"downloads":0},"search_terms":["risk","adjusted","therapy","acute","lymphoblastic","leukemia","decrease","treatment","burden","improve","survival","treatment","results","2169","unselected","pediatric","adolescent","patients","enrolled","trial","bfm","schrappe","moricke","reiter","zimmermann","gadner","stanulla","dordelmann","loning","beier","ludwig","ratei","harbott","boos","mann","niggli","feldges","henze","welte","beck","klingebiel","niemeyer","zintl","bode","urban","wehinger","niethammer","riehm","stu"],"keywords":["brain-tumors","childrens-cancer-group","clinical-significance","cranial irradiation","dana-farber","medical-research-council","multicenter randomized-trial","oncology-group","phase-iii","term follow-up"],"authorIDs":[]}